INTERPACE BIOSCIENCES, INC. (IDXG) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US46062X3035
INTERPACE BIOSCIENCES, INC. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 38.73 m USD |
| Gross profit | 24.13 m USD |
| Operating income | 4.08 m USD |
| EBIT | 3.37 m USD |
| Net income | 24.58 m USD |
| Diluted EPS – continuing operations | 0.89 USD |
Full history since 2000, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About INTERPACE BIOSCIENCES, INC.
Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States. It offers ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier. It primarily serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
More stocks
- OS Therapies Inc (OSTX)
- Ideal Power Inc. (IPWR)
- U S GLOBAL INVESTORS INC (GROW)
- Wintec Co. Ltd (320000.KQ)
- InfraCom Group AB (INFRA.ST)
- Forward Industries, Inc. (FWDI)
- High Roller Technologies, Inc. (ROLR)
- NEPHROS INC (NEPH)
- Sachem Capital Corp. (SACH)
- Vanguard Green Investment Ltd (VGES)
- HyOrc Corp (HYOR)
- Future FinTech Group Inc. (FTFT)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.